Cromatina/Epigenética
Os inibidores de cromatina/epigenética são compostos que modulam a estrutura e função da cromatina ou interferem em modificações epigenéticas, como a metilação do DNA e a modificação de histonas. Esses inibidores são ferramentas essenciais para estudar a regulação da expressão gênica e o papel da epigenética em doenças como o câncer, distúrbios neurológicos e anomalias do desenvolvimento. Ao direcionar os processos epigenéticos, esses inibidores podem alterar os padrões de expressão gênica e oferecer novas vias terapêuticas. Na CymitQuimica, oferecemos uma ampla seleção de inibidores de cromatina/epigenética de alta qualidade para apoiar sua pesquisa em biologia molecular, genética e epigenética.
Subcategorias de "Cromatina/Epigenética"
Foram encontrados 2235 produtos de "Cromatina/Epigenética"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
BRD4-BD1-IN-1
CAS:<p>BRD4-BD1-IN-1 (Compound 9a) is a BRD4-BD1 inhibitor(IC50= 38.20 μM).</p>Fórmula:C16H15BrN4O4Cor e Forma:SolidPeso molecular:407.22A2AAR/HDAC-IN-1
CAS:<p>A2AAR/HDAC-IN-1 (compound 14c) is an orally active, balanced A2AAR/HDAC dual inhibitor of A2AAR (Ki: 163.5 nM), HDAC1 (IC50: 145.3 nM). effect.</p>Fórmula:C24H21N7O2Cor e Forma:SolidPeso molecular:439.47ARTD10/PARP10-IN-2
CAS:<p>ARTD10/PARP10-IN-2: A potent, non-selective PARP inhibitor, IC50: ARTD10/PARP10 (2.0μM), ARTD1/PARP1 (9.7μM).</p>Fórmula:C12H13N3O3Cor e Forma:SolidPeso molecular:247.25BNS
CAS:<p>BNS is a potent, prolyl-hydroxylase 2 (PHD2)-selective inhibitor.</p>Fórmula:C18H16N2O6S2Pureza:98%Cor e Forma:SolidPeso molecular:420.46MARK-IN-4
CAS:<p>MARK-IN-4 inhibits microtubule kinase (MARK) effectively (IC50: 1 nM), a target for Alzheimer's therapy.</p>Fórmula:C21H23N7OSCor e Forma:SolidPeso molecular:421.52DCE_42
CAS:<p>DCE_42 is a novel EZH2 inhibitor, it also displays significant anti-proliferation activity against lymphoma cell lines.</p>Fórmula:C22H19N9O2SPureza:98%Cor e Forma:SolidPeso molecular:473.51JAK-IN-11
CAS:<p>JAK-IN-11 (R-348) is a potent and selective inhibitor of JAK, has the potential for the skin disorders treatment.</p>Fórmula:C23H22FN5O4SPureza:99.75%Cor e Forma:SolidPeso molecular:483.52PARP1-IN-9
CAS:<p>PARP1-IN-9, potent PARP1 inhibitor with 30.51 nM IC50, outperforms Olaparib in anticancer efficacy.</p>Fórmula:C18H21N3O5Cor e Forma:SolidPeso molecular:359.38BRD4 Inhibitor-25
<p>BRD4 Inhibitor-25 blocks BRD4 (BD1: IC50 0.82 μM, BD2: 1.94 μM), induces cell death in ovarian cancer, used in cancer research.</p>Fórmula:C29H27N5O6SCor e Forma:SolidPeso molecular:573.62CAY10685
CAS:<p>CAY10685, a CPTH2 analog with an alkyne for click reactions, inhibits NAT10 to study cancer-related chromatin changes.</p>Fórmula:C17H16ClN3SCor e Forma:SolidPeso molecular:329.85DNMT3A-IN-1
CAS:<p>DNMT3A-IN-1 is a potent, selective DNMT3A inhibitor with KI 9.16-18.85 μM (AdoMet) and 11.37-23.34 μM (poly dI-dC).</p>Fórmula:C30H38N6O4Cor e Forma:SolidPeso molecular:546.66NCDM-32B
CAS:<p>NCDM-32B, a novel potent and selective KDM4 inhibitor, impairs viability and transforms phenotypes of basal breast cancer.</p>Fórmula:C15H30N2O4Pureza:98%Cor e Forma:SolidPeso molecular:302.41AChE/HDAC-IN-1
CAS:<p>COX-2-IN-23 (A10) inhibits AChE & HDAC (IC50s: 0.12 & 0.23 nM), has antioxidant/metal-binding traits, and is used in Alzheimer's research.</p>Fórmula:C26H27ClN4O3Cor e Forma:SolidPeso molecular:478.97TYK2-IN-11
CAS:<p>TYK2-IN-11 (5B) selectively inhibits TYK2 (IC50: 0.016 nM) and JAK1 (IC50: 0.31 nM), aiding autoimmune and inflammatory disease research.</p>Fórmula:C18H17N5O3SCor e Forma:SolidPeso molecular:383.42SGC6870
CAS:<p>SGC6870 is a novel potent, selective, and cell-active inhibitor of PRMT6 with IC50 of 77 ± 6 nM, being selective over all other PRMTs and 23 methyltransferases.</p>Fórmula:C23H21BrN2O2SCor e Forma:SolidPeso molecular:469.39BRD4 Inhibitor-26
<p>BRD4 Inhibitor-26: blocks BRD4 (BD1 and BD2) with IC50 of 0.82 μM & 1.94 μM; used in ovarian cancer research.</p>Fórmula:C29H27N5O6SCor e Forma:SolidPeso molecular:573.62103D5R
CAS:<p>103D5R selectively inhibits hif-1α, reducing its levels in hypoxia or with cobalt ions, dose- and time-dependently.</p>Fórmula:C20H21N3O2Cor e Forma:SolidPeso molecular:335.4MAT2A-IN-6
CAS:<p>MAT2A-IN-6 inhibits MAT2A, may slow MTAP-deficient cancer cell growth, has research value in cancer.</p>Fórmula:C18H13ClF3N3O3Cor e Forma:SolidPeso molecular:411.76CP-690550A
CAS:<p>Cp-690550a is a novel JAK3 inhibitor, which is used to treat rheumatoid arthritis, graft rejection, psoriasis, and other immune-mediated diseases.</p>Fórmula:C15H21N5O2Cor e Forma:SolidPeso molecular:303.36MZ-242
CAS:<p>MZ-242 is an effective and selective inhibitor of Sirt2.</p>Fórmula:C24H27N7O3S2Pureza:98%Cor e Forma:SolidPeso molecular:525.65Antiproliferative agent-17
CAS:<p>Antiproliferative Agent-17 exhibits both antimicrobial properties against Gram-positive bacteria and anticancer activity [1].</p>Fórmula:C26H28N2OSCor e Forma:SolidPeso molecular:416.58KDOAM-25
CAS:<p>KDOAM-25, a potent KDM5 inhibitor, enhances H3K4 methylation, hampers MM1S cell growth; IC50: 71 nM (5A), 19 nM (5B), 69 nM (5C/D).</p>Fórmula:C15H25N5O2Pureza:98%Cor e Forma:SolidPeso molecular:307.39HDAC6/8/BRPF1-IN-1
CAS:<p>HDAC6/8/BRPF1-IN-1 is a cancer-research inhibitor for HDAC6, HDAC8, BRPF1 with IC50: 344-908 nM and Kd: 175.2 nM.</p>Fórmula:C18H17N3O5SCor e Forma:SolidPeso molecular:387.41UNC2327
CAS:<p>UNC2327 is a potent and selective inhibitor of protein arginine methyltransferase 3 (PRMT3) (IC50:230 nM).</p>Fórmula:C14H17N5O2SPureza:98%Cor e Forma:SolidPeso molecular:319.38AA-CW236
CAS:<p>AA-CW236 is a covalent inhibitor of human O(6)-alkylguanine DNA methyltransferase (MGMT).</p>Fórmula:C17H16ClF3N4O2Cor e Forma:SolidPeso molecular:400.78NN-390
CAS:<p>NN-390: selective HDAC6 inhibitor, IC50 9.8 μM, blood-brain barrier penetrant, potential for metastatic group 3 neural tube cancer research.</p>Fórmula:C17H16F4N2O4SCor e Forma:SolidPeso molecular:420.38EZH2-IN-9
CAS:<p>EZH2-IN-9 inhibits EZH2, targeting SET mutations linked to cancer by reducing H3K27me3 levels.</p>Fórmula:C28H32ClF2N3O5SCor e Forma:SolidPeso molecular:596.09EZH2-IN-11
CAS:<p>EZH2-IN-11, a potent E2HZ inhibitor with potential for cancer treatment, is highlighted in patent WO2019204490A1.</p>Fórmula:C28H36ClN3O5SCor e Forma:SolidPeso molecular:562.12Aurora Kinases-IN-2
CAS:<p>Aurora Kinases-IN-2 (12Aj) hinders Aurora A/B kinases (IC50: 90/152 nM), used in cancer studies.</p>Fórmula:C22H18ClN5O3Cor e Forma:SolidPeso molecular:435.86DC-BPi-11
CAS:<p>DC-BPi-11 inhibits BPTF at IC50 698 nM and significantly reduces leukemia cell growth.</p>Fórmula:C20H23N5O2SCor e Forma:SolidPeso molecular:397.49JS1310
CAS:<p>JS1310 is a selective PRMT7 inhibitor (IC50: 5 μM against human PRMT7). JS1310 has shown anti-cancer effects on different cancer cells.</p>Fórmula:C23H22FN5O3Cor e Forma:SolidPeso molecular:435.45CypD inhibitor C-9
CAS:<p>CypD inhibitor C-9 is a CypD inhibitor, it attenuates mitochondrial and cellular perturbation insulted by Aß and calcium stress.</p>Fórmula:C22H22N4O4S2Cor e Forma:SolidPeso molecular:470.56BET-IN-2
CAS:<p>BET-IN-2 is a BET inhibitor (IC50: 52 nM for BRD4-BD1).</p>Fórmula:C23H29N3OPureza:98%Cor e Forma:SolidPeso molecular:363.5PIM1-IN-6
CAS:<p>PIM1-IN-6 (5h) inhibits PIM-1 (IC50: 0.60 μM) and is cytotoxic to HCT-116 (IC50: 1.51 μM) and MCF-7 cells (IC50: 15.2 μM).</p>Fórmula:C21H18N6O4Cor e Forma:SolidPeso molecular:418.41TNKS-IN-41
CAS:<p>TNKS-IN-41 highly potent and selective inhibitor of tankyrase.</p>Fórmula:C24H22N10O2Pureza:98%Cor e Forma:SolidPeso molecular:482.5K00135
CAS:<p>K00135 (IMIDAZOPYRIDAZIN 1) is a selective inhibitor of Pim kinases and can be used in studies about gastric cancer and antileukemic therapeutics.</p>Fórmula:C18H18N4OPureza:98.16%Cor e Forma:SolidPeso molecular:306.36MC-1353
CAS:<p>MC-1353 is a potent, selective inhibitor of HDAC class I.</p>Fórmula:C16H16N2O3Cor e Forma:SolidPeso molecular:284.31PBRM1-BD2-IN-1
CAS:<p>PBRM1-BD2-IN-1: Selective PBRM1 inhibitor with Kd 0.7μM, IC50 0.2μM, useful in cancer research.</p>Fórmula:C17H19ClN2OCor e Forma:SolidPeso molecular:302.84-iodo-SAHA
CAS:<p>4-Iodo-SAHA (1k), an oral HDAC inhibitor for cancer research, has EC50s from 0.12 to 1.3 μM across various cell lines.</p>Fórmula:C14H19IN2O3Cor e Forma:SolidPeso molecular:390.22HDAC1-IN-4
CAS:<p>HDAC1-IN-4 is a potent inhibitor of Plasmodium falciparum HDAC1 (PfHDAC1) with low cytotoxicity and antimalarial effects (IC50<5 nM).</p>Fórmula:C21H24BrClN6O2Cor e Forma:SolidPeso molecular:507.82JAK-IN-20
CAS:<p>JAK-IN-20: potent oral JAK1,2,3 inhibitor with IC50s 7, 5, 14 nM respectively, good pharmacokinetics, anti-inflammatory in vivo.</p>Fórmula:C28H30FN7O2Cor e Forma:SolidPeso molecular:515.58PIM1-IN-7
CAS:<p>PIM1-IN-7 inhibits PIM-1 (IC50: 0.67μM), toxic to HCT-116/MCF-7 cells (IC50: 42.9/7.68μM).</p>Fórmula:C23H23N5OCor e Forma:SolidPeso molecular:385.46HDAC/CK2-IN-1
CAS:<p>HDAC/CK2-IN-1 (compound 38) acts as an inhibitor of HDAC1 (IC 50 = 1.46 μM), HDAC6 (IC 50 = 0.66 μM), and CK2 (IC 50 = 3.67 μM). It demonstrates promising antiproliferative effects on various cell lines, including Jurkat, MCF-7, HCT-116, and HL-60.</p>Fórmula:C15H18Br4N4O2Cor e Forma:SolidPeso molecular:605.95BRD4-BD1/2-IN-1
CAS:<p>BRD4-BD1/2-IN-1 efficiently blocks BRD4 BD-1/2 under 100 nM IC50 (US20150148375A1, cmpd 5).</p>Fórmula:C21H14F2N4O2Cor e Forma:SolidPeso molecular:392.36DPQ
CAS:<p>DPQ inhibits PARP-1, aids in neuroprotection, restores ATP, and lessens neuronal injury from NMDA.</p>Fórmula:C18H26N2O2Pureza:98%Cor e Forma:SolidPeso molecular:302.41AMPK activator 9
CAS:<p>AMPK activator 9 (ZM-6) is a potent α2β1γ1 agonist with an EC50 of 1.1 µM, potential for type 2 diabetes research.</p>Fórmula:C31H28F4N4O4Cor e Forma:SolidPeso molecular:596.57ART-IN-1
CAS:<p>ART-IN-1 (compound 7) is a selective inhibitor of PARP with IC 50 s of 19, 22, 2.4, >100, 1.1 μM for PARP2, TNKS2, PARP10, PARP14, PARP15, respectively [1].</p>Fórmula:C14H13NO2SCor e Forma:SolidPeso molecular:259.32Peficitinib hydrochloride
CAS:<p>Peficitinib HCl (ASP015K) is an oral JAK inhibitor with IC50s: JAK1 (3.9 nM), JAK2 (5.0 nM), JAK3 (0.7 nM), Tyk2 (4.8 nM).</p>Fórmula:C18H23ClN4O2Cor e Forma:SolidPeso molecular:362.86VE-465
CAS:<p>VE-465 is an inhibitor of Aurora kinase, which involves in multiple mitotic events.</p>Fórmula:C22H28N8OSCor e Forma:SolidPeso molecular:452.58PRMT5-IN-17
CAS:<p>PRMT5-IN-17 is a PRMT5-blocking compound with anticancer properties, linked to epigenetic changes.</p>Fórmula:C26H33N7O2Cor e Forma:SolidPeso molecular:475.59HDAC/NAMPT-IN-1
CAS:<p>HDAC/NAMPT-IN-1 (compound 39h) simultaneously inhibits HDAC and NAMPT, exhibiting IC 50 values ranging from 0.72 to 37081 nM for HDAC and 1618 nM for NAMPT [1].</p>Fórmula:C19H21N5O2Cor e Forma:SolidPeso molecular:351.4IACS-9571 hydrochloride
CAS:<p>IACS-9571 hydrochloride: potent TRIM24/BRPF1 inhibitor; IC50 = 8 nM (TRIM24); Kd = 31 nM (TRIM24), 14 nM (BRPF1).</p>Fórmula:C32H43ClN4O8SCor e Forma:SolidPeso molecular:679.22KDM2B-IN-4
CAS:<p>KDM2B-IN-4, from patent WO2016112284A1 as 182b, is a potent KDM2B inhibitor used in cancer research.</p>Fórmula:C24H28N2O2Cor e Forma:SolidPeso molecular:376.49CEP-8983
CAS:<p>CEP-8983 is a PARP inhibitor potentially for the treatment of solid tumours.</p>Fórmula:C18H14N2O3Pureza:98%Cor e Forma:SolidPeso molecular:306.32BRM/BRG1 ATP Inhibitor-4
CAS:<p>BRM/BRG1 ATP Inhibitor-4, a potent inhibitor of BRG1/BRM, is utilized in the research of cancers and BAF complex-related disorders.</p>Fórmula:C25H32N6O3SCor e Forma:SolidPeso molecular:496.62MAT2A-IN-7
CAS:<p>MAT2A-IN-7 inhibits MAT2A in various cancers, especially MTAP-deficient cancer cells, with potential for research use.</p>Fórmula:C17H13ClF3N3O2Cor e Forma:SolidPeso molecular:383.75Dihydro-5-azacytidine acetate
CAS:<p>Dihydro-5-azacytidine acetate (DHAC), a nucleoside analog, becomes integrated into DNA, thereby inhibiting DNA methylation, and exhibits antitumor activity [1</p>Fórmula:C10H18N4O7Pureza:98%Cor e Forma:SolidPeso molecular:306.27LT052
CAS:<p>LT052 is a BET BD1 inhibitor with anti-inflammatory activity. It mediates the BRD4/NF-κB/NLRP3 signaling inflammatory pathway.</p>Fórmula:C22H19N5O4SPureza:98.82%Cor e Forma:SolidPeso molecular:449.48Sirt2-IN-6
CAS:<p>Sirt2-IN-6 is a potent and selective inhibitor of SIRT2 (IC50: 0.815 μM) and can be used to study cancer.</p>Fórmula:C26H26N6O3SCor e Forma:SolidPeso molecular:502.59BRD4884
CAS:<p>BRD4884 is a highly selective and efficient HDAC1 and HDAC2 inhibitor that also inhibits HDAC3, used in research on neurological disorders.</p>Fórmula:C18H19FN2O2Pureza:99.19% - 99.21%Cor e Forma:SolidPeso molecular:314.35Lorpucitinib
CAS:<p>Lorpucitinib (JNJ-64251330) is a JAK kinase inhibitor used in the study of inflammatory and gastrointestinal diseases.</p>Fórmula:C22H28N6O2Pureza:99.72%Cor e Forma:SolidPeso molecular:408.5KDM2/7-IN-1
CAS:<p>KDM2/7-IN-1 is a selective histone demethylase inhibitor (IC50s: 0.2–>120 μM) that inhibits HeLa and KYSE-150 cell proliferation, epigenetic and cancer.</p>Fórmula:C15H27NO4Pureza:99.87%Cor e Forma:SolidPeso molecular:285.38BETi-211
CAS:<p>BETi-211 is a selective inhibitor BET bromodomain.</p>Fórmula:C26H29N7O3Cor e Forma:SolidPeso molecular:487.55ZYJ-25e
CAS:<p>ZYJ-25e is an oral histone deacetylase inhibitor (HDACi) with potent antitumor activities.</p>Fórmula:C30H40N4O8Pureza:98%Cor e Forma:SolidPeso molecular:584.66IND 1316
CAS:<p>IND 1316 is an activator of AMP-activated protein kinase (AMPK).</p>Fórmula:C22H17NO3Cor e Forma:SolidPeso molecular:343.38CCT077791
CAS:<p>CCT077791 is a potent inhibitor of p300 and PCAF histone acetyltransferase activity for cancer research.</p>Fórmula:C9H5ClN2O3SPureza:98.60%Cor e Forma:SolidPeso molecular:256.67ZIKV-IN-2
CAS:<p>ZIKV-IN-2 blocks ZIKV replication, is a strong NS5 MTase inhibitor (IC50: 38.86 μM), and aids Zika virus research.</p>Fórmula:C39H42O4Cor e Forma:SolidPeso molecular:574.75KU-0058684
CAS:<p>KU-0058684 is a potent PARP and DNA-PK inhibitors.</p>Fórmula:C19H14FN3O3Cor e Forma:SolidPeso molecular:351.33ML753286
CAS:<p>ML753286 has high permeability and low to medium clearance in rodent and human liver S9 fractions.</p>Fórmula:C20H25N3O3Pureza:98%Cor e Forma:SolidPeso molecular:355.43Trotabresib
CAS:<p>Trotabresib (CC-90010) is an orally active inhibitor of BET and can be used in studies about advanced solid tumors.</p>Fórmula:C21H21NO4SPureza:99.86%Cor e Forma:SolidPeso molecular:383.46JAK1-IN-4
CAS:<p>JAK1-IN-4 selectively blocks JAK1 (IC50 = 85 nM) over JAK2/JAK3 and halts STAT3 phosphorylation in NCI-H 1975 cells (IC50 = 227 nM).</p>Fórmula:C26H32FN9O2Pureza:98%Cor e Forma:SolidPeso molecular:521.59Y02224
CAS:<p>Y02224 is a BET inhibitor. It shows the reasonable antiproliferative effect on leukemia cells.</p>Fórmula:C20H17BrN2O4SPureza:98%Cor e Forma:SolidPeso molecular:461.33Dot1L-IN-5
CAS:<p>Dot1L-IN-5 is a potent inhibitor of the disruptor of telomeric silencing 1-like protein ( DOT1L ) with an IC 50 SPA DOT1L of 0.17 nM [1].</p>Fórmula:C23H19ClF2N8O5SCor e Forma:SolidPeso molecular:592.96HAT-IN-1
CAS:<p>HAT-IN-1 is an inhibitor of HAT used in the research of cancer.</p>Fórmula:C23H18BrF4N3O4Pureza:98%Cor e Forma:SolidPeso molecular:556.3Helenalin Acetate
CAS:<p>Helenalin Acetate: anti-inflammatory, anti-cancer, hinders C/EBPß and p300 cooperation.</p>Fórmula:C17H20O5Pureza:98%Cor e Forma:SolidPeso molecular:304.34HDAC-IN-45
CAS:<p>HDAC-IN-45, a small HDAC blocker, forms H-bonds with Y303 and shows anticancer properties; IC50 for HDAC1/2/3: 0.108/0.585/0.563 μM.</p>Fórmula:C25H20ClFN8OCor e Forma:SolidPeso molecular:502.93DM-01
CAS:<p>DM-01 is a potent and selective inhibitor of EZH2.</p>Fórmula:C23H24F3N3O2Cor e Forma:SolidPeso molecular:431.45dBRD9-A
CAS:<p>Potent BRD9 degrader that binds selectively, fully degrades BRD9 at low doses, and hinders synovial sarcoma growth in vitro and in mice.</p>Fórmula:C42H49N7O8Cor e Forma:SolidPeso molecular:779.88PB118
<p>PB118 clears Aβ, boosts phagocytosis, enhances tubulin networks, reduces p-tau & inflammation in AD; HDAC6 IC50: 5.6 nM.</p>Fórmula:C18H19FN2O2Cor e Forma:SoildPeso molecular:314.35Dot1L-IN-7
CAS:<p>Dot1L-IN-7 (compound 25), a potent DOT1L inhibitor with an IC50 of 1.0 μM, selectively kills MLL-AF9, sparing E2A-HLF cells.</p>Fórmula:C23H27N9O2Cor e Forma:SolidPeso molecular:461.52CeMMEC2
CAS:<p>CeMMEC2, a novel inhibitor of BRD4, binds both the first and the second bromodomain of BRD4.</p>Fórmula:C14H19N5Cor e Forma:SolidPeso molecular:257.33(1S,2R)-Tranylcypromine hydrochloride
CAS:<p>(1S,2R)-Tranylcypromine hydrochloride ((1S,2R)-SKF 385), a potent antidepressant, functions by inhibiting both MAO and LSD1.</p>Fórmula:C9H12ClNCor e Forma:SolidPeso molecular:169.651Guadecitabine sodium
CAS:<p>Guadecitabine sodium is a inhibitor of second-generation DNA methyltransferases (DNMT) .</p>Fórmula:C18H24N9NaO10PPureza:98%Cor e Forma:SolidPeso molecular:580.407HDAC6-IN-46
CAS:<p>HDAC6-IN-46 (compound 12) is a selective inhibitor of histone deacetylase 6 (HDAC6), exhibiting an IC50 of 6.2 nM. It is utilized in research related to Alzheimer's disease.</p>Fórmula:C26H21N3O4Cor e Forma:SolidPeso molecular:439.46HDAC3-IN-T326
CAS:<p>HDAC3-IN-T326: potent, selective HDAC3 inhibitor, boosts NF-κB acetylation, activates latent HIV gene expression.</p>Fórmula:C21H18N6O3SPureza:98%Cor e Forma:SolidPeso molecular:434.47Gue1654
CAS:<p>Gue1654 is an OXE-R inhibitor and cardiomyocyte apoptosis.Gue1654 can be used for the study of cardiovascular diseases.</p>Fórmula:C23H17N3OS3Pureza:98.02% - 98.04%Cor e Forma:SolidPeso molecular:447.6LSD1-IN-6
CAS:<p>LSD1-IN-6, a potent LSD1 inhibitor (IC50: 123 nM), enhances H3K4me2 without altering LSD1 expression. Reversible.</p>Fórmula:C15H13BrN2O3Pureza:98%Cor e Forma:SolidPeso molecular:349.18SC-9
CAS:<p>SC-9 is a protein kinase C activator.</p>Fórmula:C22H24ClNO2SPureza:98%Cor e Forma:SolidPeso molecular:401.95PS432
CAS:<p>PS432 inhibits atypical PKCs, targets PIF-pocket, reduces tumors in mice sans side effects.</p>Fórmula:C25H19ClN2O5SPureza:98%Cor e Forma:SolidPeso molecular:494.95SMYD2-IN-1
CAS:<p>SMYD2-IN-1 is an inhibitor of SMYD2 (IC50 of 4.45 nM).</p>Fórmula:C25H25Cl2F2N7O2Pureza:98%Cor e Forma:SolidPeso molecular:564.41Piribedil dihydrochloride
CAS:<p>dopamine agonist</p>Fórmula:C16H20Cl2N4O2Pureza:98%Cor e Forma:SolidPeso molecular:371.26Akt Inhibitor X
CAS:<p>Akt Inhibitor X is a cell-permeable and reversible inhibitor of Akt phosphorylation.</p>Fórmula:C20H25ClN2OPureza:98%Cor e Forma:SolidPeso molecular:344.88KDM5B-IN-3
CAS:<p>KDM5B-IN-3 inhibits KDM5B/JARID1B with IC50 of 9.32 μM, useful in gastric cancer studies.</p>Fórmula:C19H25ClN4O2Cor e Forma:SolidPeso molecular:376.88DDP-38003 dihydrochloride
CAS:<p>DDP-38003 dihydrochloride is an orally available histone lysine-specific demethylase 1A (KDM1A/LSD1) inhibitor (IC50: 84 nM).</p>Fórmula:C21H28Cl2N4OPureza:99.76%Cor e Forma:SolidPeso molecular:423.38CID-4785700
CAS:<p>CID-4785700 is a potent pan-GTPase inhibitor that inhibits Rab7 and inhibits the fungal histone acetyltransferase Rtt109 that binds to Asf1 and Vps75</p>Fórmula:C22H23ClFN3O3Pureza:98.16%Cor e Forma:SolidPeso molecular:431.89Kgp-IN-1
CAS:<p>Kgp-IN-1 is an arginine-specific gingipain (Rgp) inhibitor.</p>Fórmula:C19H24F4N4O3Pureza:98%Cor e Forma:SolidPeso molecular:432.41PARP-1/2-IN-1
CAS:<p>PARP-1-/2-IN-1 is a potent inhibitor of PARP-1 (IC50: 0.51 nM) and PARP-2 (IC50: 23.11 nM).</p>Fórmula:C24H27FN4O3Cor e Forma:SolidPeso molecular:438.49NSC-636819
CAS:<p>NSC-636819 is a novel inhibitor of KDM4A/KDM4B.</p>Fórmula:C22H12Cl4N2O4Pureza:98%Cor e Forma:SolidPeso molecular:510.15M-110
CAS:<p>M-110 selectively targets PIM kinases, best at PIM-3 (IC50=47nM), and inhibits prostate cancer cell growth (IC50=0.6-0.9μM).</p>Fórmula:C22H28ClN5O3Pureza:99.55%Cor e Forma:SolidPeso molecular:445.94MI-1
CAS:<p>MI-1 inhibits Menin-MLL interaction with an IC 50 of 1.9 μM [1].</p>Fórmula:C19H25N5S2Cor e Forma:SolidPeso molecular:387.57
